

# ForPatients

by Roche

Spinal Muscular Atrophy (SMA)

## A study to investigate the safety, tolerability, and pharmacokinetics/ pharmacodynamics of risdiplam in adult and paediatric patients with spinal muscular atrophy

**Trial Status**

Active, not recruiting

**Trial Runs In**

9 Countries

**Trial Identifier**

NCT03032172

2016-004184-39,2023-506739-14-00

BP39054

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a multi-center, exploratory, non-comparative, and open-label study to investigate the safety, tolerability, PK, and PK/PD relationship of risdiplam in adults, children and infants with Spinal Muscular Atrophy (SMA) previously enrolled in Study BP29420 (Moonfish) with the splicing modifier RO6885247 or previously treated with nusinersen, olesoxime or AVXS-101.

**Hoffmann-La Roche**

Sponsor

**Phase 2**

Phase

**NCT03032172 2016-004184-39,2023-506739-14-00 BP39054**

Trial Identifiers

### *Eligibility Criteria:*

**Gender**

All

**Age**

>= 6 Months & <= 60 Years

**Healthy Volunteers**

No

### **1. Why is this study needed?**

Spinal muscular atrophy (SMA) is a rare genetic disorder that causes weakness and wasting (atrophy) in muscles used for movement. It is caused by loss of certain specialised nerve cells called motor neurons that transmit signals from the brain to the muscles, enabling movement. The cause of SMA is a structural change in a section of a gene called survival of motor neuron (SMN). The normal SMN gene provides instructions for SMN protein production. In people with SMA, due to a lack of normal SMN protein, the function of the special nerve cells that enable movement is affected.

# ForPatients

*by Roche*

This study is testing a medicine called risdiplam (RO7034067), which is the first drug to be given by mouth for treatment of SMA. Risdiplam is approved for use in patients with SMA, however, it is considered an experimental drug for the purpose of this study.

This study aims to find out the safety of risdiplam, how well the body handles it, and to understand how risdiplam gets to different parts of the body, how the body changes and gets rid of it in people living with SMA who have received other medicines for SMA.

## **2. Who can take part in the study?**

People living with SMA between 6 months to 60 years of age are taking part in this study. People who previously took part in study BP39420 (Moonfish) or were previously treated with other SMA medicines called nusinersen (SPINRAZA), AVXS-101 (ZOLGENSMA) or olesoxime only could participate in this study.

People having any other major existing condition or who received any protocol-specified medicines previously, were not able to take part in this study.

People who were pregnant, or breastfeeding could not participate in the study.

## **3. How does this study work?**

People with SMA were screened to check if they could participate in the study. The screening took place for about 28 days before the start of treatment.

Everyone who joined this study is given a daily oral dose of risdiplam as a liquid medicine. The doses of risdiplam depend on the participant's body weight. Participants initially received risdiplam for 2 years. After completion of 2 years, they were given an opportunity to continue receiving risdiplam in the extension phase of this study for the next 3 years. Participants have regular blood tests and are checked for unwanted effects throughout the study.

This is an open-label study. This means everyone involved, including the participant and the study doctor, will know the study treatment the participant has been given.

During this study, the study doctor met the participants four times during the first month and then every 3 months thereafter. They will see how well the treatment is working and any unwanted effects participants may have. Participants will have a follow-up telephone call from the study doctor to check on their well-being at 30 days of completing the study treatment. This follow-up call will be conducted only for participants who stop risdiplam treatment. Total time of participation in the study will be approximately 5 years. Participants have the right to stop study treatment and leave the study at any time, if they wish to do so.

# ForPatients

*by Roche*

## **4. What are the main results measured in this study?**

The main results measured in the study to assess if the medicine has worked as expected are:

- The number of participants with unwanted effects and the severity of the unwanted effects which will be assessed from the start of study treatment up to 5 years.
- How well the body processes risdiplam, which was assessed for up to 2 years.

The study additionally collected information about changes in the levels of SMN protein in blood which was measured from the start of the study up to 2 years.

## **5. Are there any risks or benefits in taking part in this study?**

Taking part in the study may or may not make participants feel better. But the information collected in the study can help other people with similar health conditions in the future.

The study involves some risks to the participant. But these risks are generally not greater than those related to routine medical care or the natural progression of SMA. People interested in taking part were informed about the risks and benefits, as well as any additional procedures or tests they may need to undergo. All details of the study were described in an informed consent document. This included information about possible effects and other options of treatment.

### **Risks associated with risdiplam**

Participants may have unwanted effects of the drug used in this study. These unwanted effects can be mild to severe and vary from person to person. During this study, participants will have regular check-ups to see if there are any unwanted effects.

Participants were told about the known unwanted effects of risdiplam, and possible unwanted effects based on human and laboratory studies or knowledge of similar medicines. Known unwanted effects include cold, runny nose, headache, frequent watery stools (diarrhoea), vomiting and rash.

Risdiplam is given as a liquid medicine to be taken by mouth.

The study medicine may be harmful to an unborn baby. Women and men must take precautions to avoid exposing an unborn baby to the study treatment.